ServiziMenu principaleHome
Home > Sponsors & Exhibition > Sponsored satellite symposia

Sponsored satellite symposia

Thursday, 14 November

9:00 -10:30 Sponsored satellite symposium 1 TouchIME
This activity is supported by an educational grant from Eli Lilly and Company. This activity is jointly provided by Oakstone Publishing and touchIME.


Are we moving towards true optimization of CDK4/6 inhibition in patients with HR+/HER2- advanced breast cancer?

  9:00 Introduction and welcome (Chair: Patrick Neven, BE)
  9:10 How can we select the most appropriate CDK4/6 inhibitor and treatment sequencing in patients with 
          HR+/HER2- ABC? (Rupert Bartsch, AT and Shaheenah Dawood, AE)
  9:35 How different are the AE profiles for the CDK4/6 inhibitors and what impact do they have on monitoring and
          adherence? (Patrick Neven, BE)
10:00 How might upcoming guidelines be updated in light of recent data? (Rupert Bartsch, AT - Shaheenah Dawood, AE and Patrick Neven, BE)
10:25 Summary and close (Patrick Neven, BE)

Symposium faculty
Rupert Bartsch, Medical University of Vienna, Vienna, AT
Shaheenah Dawood
, Dubai Medical College, Dubai, AE
Patrick Neven, Universitair Ziekenhuis Leuven, Leuven, BE

11:00 -12:30
Sponsored satellite symposium 2 Novartis


Progress in HR+/HER2- advanced breast cancer: hopes and challenges in clinical practice

11:00 Welcome (Luis Costa, PT)
11:05 Panel I. Progress in HR+ HER2- aBC: Translating cancer biology knowledge into benefit for patients
         - Presentation (Richard de Boer, AU)
         - Interactive panel discussion (Richard de Boer, AU - Luis Costa, PT - Peter Fasching, DE - Mark Tuthill, UK
           and Andrew Wardley, UK)
11:35 Panel II. Progress in HR+ HER2- aBC: the evolving role of biomarkers
         - Presentation (Peter Fasching, DE)
         - Interactive panel discussion (Richard de Boer, AU - Luis Costa, PT - Peter Fasching, DE - Mark Tuthill, UK
           and Andrew Wardley, UK)
12:05 Progress in HR+ HER2- aBC: how will the future look?
         - Interactive panel discussion (Richard de Boer, AU - Luis Costa, PT - Peter Fasching, DE - Mark Tuthill, UK
           and Andrew Wardley, UK)
12:25 Closing remarks (Luis Costa, PT)

Symposium faculty
Luis Costa
, Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria, Lisbon, PT
Richard De Boer, Peter MacCallum Cancer Centre, Melbourne, AU
Peter Fasching, University Hospital Erlangen, DE
Mark Tuthill, Churchill Hospital, Oxford, UK
Andrew Wardley, The Christie Hospital, Manchester, UK

18:00 -19:30 Sponsored satellite symposium 3 Daiichi Sankyo Europe


HER2 targeted therapies in metastatic Breast Cancer - Current Status and Emerging Options
Chair: Chris Twelves, UK

18:00 Introduction and objectives of the meeting (Chris Twelves, UK)
18:10 Current challenges in HER2 targeted therapies – where do we need further improvement?
          - The clinician’s perspective (Sofia Braga, PT)
          - The pathologist’s perspective (Giuseppe Viale, IT)
18:40 How can new technologies fill the medical gap in HER driven metastatic Breast Cancer? (Peter Fasching, DE)
18:55 Clinical study programs to optimize personalized medicine in Her2 metastatic breast cancer
          (Jean-Yves Pierga, FR)
19:10 Panel discussion (All and moderated by Chris Twelves, UK)
19:25 Key take away and closing (Chris Twelves, UK)

Symposium faculty
Sofia Braga, Minho University, Braga, PT
Peter Fasching, University Erlangen, Erlangen, DE
Jean-Yves Pierga, Institut Curie, Paris, FR
Chris Twelves, Clinical Cancer Pharmacology and Oncology, Leeds, UK
Giuseppe Viale, University of Milan, Milan, IT

Friday, 15 November

18:00 -19:30 Sponsored satellite symposium 5 Pierre Fabre

Treatment options and recent advances in HER2-positive breast cancer
Chairs: Hans-Joachim Lück, DE and Cristina Saura, ES

18:00 Introductory comments (Hans-Joachim Lück, DE)
18:05 State of the art of early-stage therapy in HER2-positive breast cancer (John Crown, IE)
18:25 What can we learn from recent trials? (Edith Perez, US)
18:45 The evolving landscape of treatment of advanced HER2-positive disease (Cristina Saura, ES)
19:05 Optimizing the risks and benefits of treatments (Barbara Pistilli, FR)
19:25 Summary and Conclusions (Cristina Saura, ES)

Symposium faculty
John Crown, St Vincent’s University Hospital, Dublin, IE
Hans-Joachim Lück, Gynäkologisch Onkologische Schwerpunktpraxis, Hannover, DE
Edith Perez, Mayo Clinic, Jacksonville, US
Barbara Pistilli, Institut Gustave Roussy, Villejuif, FR
Cristina Saura, Instituto de Oncologia Vall d’Hebron, Barcelona, ES